Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: PF-00299804

First Posted Date: 2009-09-03

Last Posted Date: 2012-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT00971191

Locations: 🇺🇸
Pfizer Investigational Site, Los Angeles, California, United States

Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: OAP-189
Drug: placebo comparator

First Posted Date: 2009-09-02

Last Posted Date: 2020-11-02

Lead Sponsor: Pfizer

Target Recruit Count: 92

Registration Number: NCT00970593

Locations: 🇺🇸
Profil Institute for Clincal Research, Chula Vista, California, United States
🇺🇸
Cetero Research - Miami, Miami Gardens, Florida, United States

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: CP-690,550

First Posted Date: 2009-09-01

Last Posted Date: 2010-02-11

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT00969813

Locations: 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: PF-02341066

First Posted Date: 2009-08-26

Last Posted Date: 2015-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00965731

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
James Care in Kenny, Columbus, Ohio, United States

and more 12 locations

Genotropin Study Assessing Use of Injection Pen

Phase 3

Completed

Conditions: Growth Hormone Deficiency
Idiopathic Short Stature

Interventions: Device: New Genotropin Pen

First Posted Date: 2009-08-25

Last Posted Date: 2011-01-28

Lead Sponsor: Pfizer

Target Recruit Count: 136

Registration Number: NCT00965484

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

Phase 3

Completed

Conditions: HIV Infections
Pneumococcal Infections

Interventions: Biological: 13-valent pneumococcal conjugate vaccine
Procedure: Blood draw

First Posted Date: 2009-08-21

Last Posted Date: 2013-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 331

Registration Number: NCT00963235

Locations: 🇺🇸
Pfizer Investigational Site, Dallas, Texas, United States

Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

Phase 3

Completed

Conditions: Arthritis, Juvenile Idiopathic

Interventions: Drug: Etanercept

First Posted Date: 2009-08-20

Last Posted Date: 2014-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 127

Registration Number: NCT00962741

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

Effects of ICA-105665 Using the Intradermal Capsaicin and Ultraviolet B (UV-B) Models in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ICA-105665
Drug: Placebo
Drug: Ibuprofen

First Posted Date: 2009-08-20

Last Posted Date: 2012-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT00962663

Locations: Pfizer Investigational Site

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

Phase 3

Completed

Conditions: HIV Infections
Pneumococcal Infections

Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Procedure: Blood draw

First Posted Date: 2009-08-20

Last Posted Date: 2014-11-17

Lead Sponsor: Pfizer

Target Recruit Count: 303

Registration Number: NCT00962780

Locations: 🇿🇦
Pfizer Investigational Site, Paarl, South Africa

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Conditions: Gaucher Disease

First Posted Date: 2009-08-19

Last Posted Date: 2018-09-07

Lead Sponsor: Pfizer

Registration Number: NCT00962260

Locations: 🇮🇱
Sha'are Zedek Medical Center, Jerusalem, Israel
🇺🇸
University Research Foundation for Lysosomal Storage Diseases, Inc., Coral Springs, Florida, United States
🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy